March 31, 2014 / 2:33 PM / 4 years ago

MARKET PULSE-Prana, Nordion, UTi Worldwide, Novartis, Halozyme

(For more market insights, including options activity, click on ; for the Day Ahead newsletter; for the Morning News Call newsletter, U.S. stock indexes opened higher on Monday, putting the S&P 500on track for a second straight advance, ahead of a speech by Federal Reserve Chair Janet Yellen. The Dow Jones industrial average was up 0.81 percent at 16,454.48, the S&P 500 was up 0.79 percent at 1,872.23 and the Nasdaq Composite was up 1.13 percent at 4,202.8.

** PRANA BIOTECHNOLOGY LTD, $2.94, -70.18 pct

The company said its experimental drug to treat Alzheimer’s disease failed to meet the main goal of a mid-stage study in patients with a mild form of the condition.

** NORDION INC, $11.56, +11.05 pct

Sterigenics, a sterilization services provider owned by private equity firm GTCR LLC, has reached a deal to buy Canadian medical isotopes supplier Nordion for $727 million.

** UTI WORLDWIDE INC, $10.42, -7.46 pct

The logistics company reported a bigger-than-expected quarterly loss, hurt by weak demand for air freight as customers opt for slower, but cheaper, modes of shipping.

** CURIS INC, $2.8, +1.82 pct

The company said the U.S. Food and Drug Administration allowed it to resume testing its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial.

** HALOZYME THERAPEUTICS INC, $12.62, +4.21 pct

The company said its U.S. FDA-approved drug, Hylenex, met the main goal in a trial testing its use as a pre-treatment in type 1 diabetes patients receiving continuous insulin infusions, compared to those who received no pre-treatment.

The trial’s results will be part of the data used to seek an update to the Hylenex label, the company said on Monday.

** MEDTRONIC INC, $60.98, +0.94 pct

A non-surgically implanted heart valve meant to delay open heart surgery in children with congenital heart defects worked well for all but a few patients during a year of follow-up observation, in line with favorable results seen in original clinical trials of the Medtronic product.

** BLACKBERRY LTD, $8.075, -3.98 pct

The company reported a smaller-than-expected loss on Friday as new chief executive John Chen slashed costs, but a 64 percent drop in revenue underscored the challenge Chen faces in turning around the struggling smartphone maker.

** YAHOO INC, $36.495, +1.66 pct

Yahoo is working on a service similar to Google Inc's YouTube, and is hoping to launch it in the next few months, technology blog Recode reported late on Friday, quoting sources close to the situation. (

Yahoo is working on a plan to lure some of YouTube’s most popular stars and networks to show their stuff on the site, the blog said.

** TIME WARNER CABLE INC, $137.05, +0.87 pct

** COMCAST CORP, $49.965, +1.28 pct

Comcast is planning to increase its share buyback plan by more than 80 percent as its $45 billion takeover of Time Warner undergoes regulatory review in the coming weeks, Bloomberg reported.

** FOREST LABORATORIES, $92.2, +0.72 pct

Hungarian drug maker Gedeon Richter and its partner Forest Laboratories announced positive top-line results from a Phase IIb trial of antipsychotic drug Cariprazine in patients with bipolar depression, the companies said in a statement on Monday.

** NOVARTIS AG, $85.01, +4.19 pct

Novartis has ended a late-stage clinical trial of a chronic heart failure drug early, following strong interim results, giving the Swiss drugmaker a boost after recent setbacks to another heart failure medicine.

** EDWARDS LIFESCIENCES CORP, $73.93, +3.89 pct

The minimally invasive aortic heart valve replacement system from Edwards Lifesciences performed better than a rival product sold by Medtronic in the first head-to-head study of the two, according to data from a small German trial presented at a major heart meeting on Sunday.

** INTEROIL CORP, $64.38, +1.53 pct

The oil and gas company reported bigger revenue for the fourth quarter, helped by its midstream refining business. Revenue rose 12 percent to $398.9 million in the quarter ended Dec. 31. Revenue from the midstream refining business jumped 17 percent to $353.7 million.

** AMGEN INC, $124.32, +3.13 pct

The company’s drug from a high profile new class of experimental medicines lowered “bad” LDL cholesterol by 55 percent to 66 percent compared with a placebo in a trio of late-stage clinical trials, according to data presented on Saturday. (Compiled by Abhirup Roy in Bangalore; Editing by Maju Samuel)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below